SG10202002926UA - Compositions and methods for inhibiting cancer stem cells - Google Patents

Compositions and methods for inhibiting cancer stem cells

Info

Publication number
SG10202002926UA
SG10202002926UA SG10202002926UA SG10202002926UA SG10202002926UA SG 10202002926U A SG10202002926U A SG 10202002926UA SG 10202002926U A SG10202002926U A SG 10202002926UA SG 10202002926U A SG10202002926U A SG 10202002926UA SG 10202002926U A SG10202002926U A SG 10202002926UA
Authority
SG
Singapore
Prior art keywords
compositions
methods
stem cells
cancer stem
inhibiting cancer
Prior art date
Application number
SG10202002926UA
Inventor
Elaine Hurt
Ralph Minter
Steven Rust
Alan Sandercock
Sotirios Karathanasis
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG10202002926UA publication Critical patent/SG10202002926UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
SG10202002926UA 2015-09-30 2016-09-29 Compositions and methods for inhibiting cancer stem cells SG10202002926UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235144P 2015-09-30 2015-09-30

Publications (1)

Publication Number Publication Date
SG10202002926UA true SG10202002926UA (en) 2020-05-28

Family

ID=57121217

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202002926UA SG10202002926UA (en) 2015-09-30 2016-09-29 Compositions and methods for inhibiting cancer stem cells

Country Status (13)

Country Link
US (2) US11192948B2 (en)
EP (1) EP3356414A1 (en)
JP (1) JP6938478B2 (en)
KR (1) KR20180054818A (en)
CN (1) CN108290952B (en)
AU (2) AU2016329409B2 (en)
CA (1) CA3000285A1 (en)
HK (2) HK1255053A1 (en)
IL (1) IL258242B2 (en)
MA (1) MA43342A (en)
RU (2) RU2021120719A (en)
SG (1) SG10202002926UA (en)
WO (1) WO2017055511A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123405A1 (en) * 2018-12-21 2022-11-30 23Andme Inc ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF
CN111303280B (en) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 High-neutralization-activity anti-SARS-CoV-2 fully human monoclonal antibody and application

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2849556A1 (en) 2002-04-11 2003-10-23 Vu Truong-Le Preservation of bioactive materials by freeze dried foam
KR20050011741A (en) 2002-04-11 2005-01-29 메드이뮨 백신즈 인코포레이티드 Preservation of bioactive materials by spray drying
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1581639A4 (en) 2002-12-17 2006-03-08 Medimmune Vaccines Inc High pressure spray-dry of bioactive materials
JP2006022063A (en) * 2004-07-09 2006-01-26 Univ Nihon Lox-1 gene expression inhibitor
US8481314B2 (en) * 2007-02-23 2013-07-09 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
US20090311271A1 (en) * 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
US8628959B2 (en) 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
WO2013119964A2 (en) * 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) * 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
DE112012000990B4 (en) 2011-02-24 2024-06-27 Aspira Women's Health Inc. (n.d.Ges.d.Staates Delaware) Biomarker panels, diagnostic procedures and test kits for ovarian cancer
US20150238586A1 (en) 2012-08-15 2015-08-27 California Stem Cell, Inc. Rapid Method Production High Purity Cancer Stem Cells and Population of High Purity Cancer Stem Cells
UY35620A (en) * 2013-06-21 2015-01-30 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
NZ729600A (en) 2014-10-01 2023-09-29 Medimmune Ltd Binding proteins specific for lox1 and uses thereof

Also Published As

Publication number Publication date
JP6938478B2 (en) 2021-09-22
CN108290952A (en) 2018-07-17
EP3356414A1 (en) 2018-08-08
AU2020201276A1 (en) 2020-03-12
AU2020201276B2 (en) 2022-03-17
AU2016329409B2 (en) 2019-11-28
IL258242B2 (en) 2023-02-01
MA43342A (en) 2018-08-08
US11192948B2 (en) 2021-12-07
IL258242A (en) 2018-05-31
AU2016329409A1 (en) 2018-05-10
CA3000285A1 (en) 2017-04-06
JP2018529716A (en) 2018-10-11
CN108290952B (en) 2023-05-02
US20220195037A1 (en) 2022-06-23
WO2017055511A1 (en) 2017-04-06
RU2021120719A (en) 2021-11-03
IL258242B (en) 2022-10-01
US20180273616A1 (en) 2018-09-27
RU2752610C1 (en) 2021-07-29
HK1257189A1 (en) 2019-10-18
KR20180054818A (en) 2018-05-24
HK1255053A1 (en) 2019-08-02

Similar Documents

Publication Publication Date Title
HK1257295A1 (en) Compositions and methods for immunooncology
HK1243333A1 (en) Methods and compositions for modified t cells
IL304820A (en) Compositions and methods for treating cancer
HK1251610A1 (en) Compositions and methods for inhibiting factor d
PT3377516T (en) Methods and compositions for treating cancer
GB201513304D0 (en) Compositions and Methods
HUE054673T2 (en) Methods and compositions for treating cancer
IL256523A (en) Compositions and methods for treating cancer
HK1258528A1 (en) Methods and compositions for stem cell transplantation
HK1245158A1 (en) Apilimod compositions and methods for using same
IL246607B (en) Improved cell compositions and methods for cancer therapy
EP3213752A4 (en) Composition for treating cancer stem cells
SG11201701237QA (en) Compositions for modulating cancer stem cells and uses therefor
EP3286179A4 (en) Compositions and methods for inhibiting kinases
LT3586821T (en) Stem cell stimulating compositions and methods
GB201613078D0 (en) Stem cells and cancer
IL255638A (en) Compositions and methods for treating cancer
HK1257189A1 (en) Compositions and methods for inhibiting cancer stem cells
GB201512996D0 (en) Compositions and methods
HK1250958A1 (en) Compositions and methods for treating cancer
GB201514413D0 (en) Compositions and methods
GB201514415D0 (en) Compositions and methods